中华放射肿瘤学杂志最新文献

筛选
英文 中文
Current situation of clinical research of buccal mucosa squamous cell carcinoma 口腔黏膜鳞状细胞癌的临床研究现状
Chinese Journal of Radiation Oncology Pub Date : 2020-04-15 DOI: 10.3760/CMA.J.CN113030-20190715-00011
Xiaoyang Liu, Xuewen Liu, Hui Wang
{"title":"Current situation of clinical research of buccal mucosa squamous cell carcinoma","authors":"Xiaoyang Liu, Xuewen Liu, Hui Wang","doi":"10.3760/CMA.J.CN113030-20190715-00011","DOIUrl":"https://doi.org/10.3760/CMA.J.CN113030-20190715-00011","url":null,"abstract":"Treatment approaches for buccal mucosa carcinoma include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and various combinations of these modalities, whereas the clinical efficacy is not satisfactory. In this article, literature review was conducted to summarize the current situation of the diagnosis, lymph node metastasis, treatments of buccal mucosa carcinoma, aiming to provide reference for clinical practice. \u0000 \u0000Key words: \u0000Buccal mucosa squamous cell carcinoma/chemoradiotherapy; Buccal mucosa squamous cell carcinoma/immunotherapy; Lymph node metastasis; Current situation","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"304-307"},"PeriodicalIF":0.0,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42741893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism of radiation combined with recombinant human endostatin in inducing myocardial fibrosis 放射联合重组人内皮抑素诱导心肌纤维化的机制
Chinese Journal of Radiation Oncology Pub Date : 2020-04-15 DOI: 10.3760/CMA.J.CN113030-20190911-00009
Yanfang Wan, W. Ouyang, S. Su, Jun Zhang, Shi-Lin Xu, Zhu Ma, Qingsong Li, Y. Geng, B. Lu
{"title":"Mechanism of radiation combined with recombinant human endostatin in inducing myocardial fibrosis","authors":"Yanfang Wan, W. Ouyang, S. Su, Jun Zhang, Shi-Lin Xu, Zhu Ma, Qingsong Li, Y. Geng, B. Lu","doi":"10.3760/CMA.J.CN113030-20190911-00009","DOIUrl":"https://doi.org/10.3760/CMA.J.CN113030-20190911-00009","url":null,"abstract":"Objective \u0000The experimental animal model was established to unravel the mechanism of radiation-induced myocardial fibrosis and validate the role of recombinant human endostatin in aggravating the process of radiation-induced myocardial fibrosis via the TGF-β 1, Smad2 and Smad3 signaling pathways. \u0000 \u0000 \u0000Methods \u0000Sixty male adult Sprague-Dawley rats were randomly divided into the following groups: radiotherapy (RT)25 Gy, recombinant human endostatin (RE) 6 mg/kg, RE 12 mg/kg, RT 25 Gy+ RE 6 mg/kg, RT 25 Gy+ RE 12 mg/kg and blank control groups. Five rats were sacrificed in each group at 1 and 3 months after interventions. The myocardial tissues were collected. The pathological changes were observed by Hematoxylin and eosin staining. The degree of fibrosis was assessed by Masson trichrome staining. The expression levels of TGF-β1, Smad2, Smad3 and Collagen-I mRNA and protein were quantitatively measured by real-time PCR and Western blotting. \u0000 \u0000 \u0000Results \u0000At 3 months after intervention, Masson trichrome staining revealed that the collagen deposition in the RT 25Gy and RT 25Gy+ RE (6 and 12 mg/kg) groups was more significant than that in the control group. In addition, The expression levels of TGF-β1, Smad2, Smad3 and Collagen-I mRNA and protein in these groups were significantly up-regulated compared with those in the control group. \u0000 \u0000 \u0000Conclusions \u0000Radiation with a total physical dose of 25 Gy can induce myocardial fibrosis in the SD rat models. TGF-β 1 and Smad2 signaling pathways are the common signaling pathways of myocardial fibrosis induced by radiation combined with recombinant human endostatin. \u0000 \u0000 \u0000Key words: \u0000Radiation-induced heart disease; Recombinant human endostatin; TGF-β1 gene; Smad2 gene; Smad3 gene; Collagen-I gene","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"294-299"},"PeriodicalIF":0.0,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41524314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of LncRNA UCA1 on radiosensitivity of lung cancer cells and its mechanism LncRNA UCA1对肺癌细胞放射敏感性的影响及其机制
Chinese Journal of Radiation Oncology Pub Date : 2020-04-15 DOI: 10.3760/CMA.J.CN113030-20190618-00008
Cheng Wang, Zongwen Liu, Ge Hou, Jun Yang, Yang-yang Huang
{"title":"Effect of LncRNA UCA1 on radiosensitivity of lung cancer cells and its mechanism","authors":"Cheng Wang, Zongwen Liu, Ge Hou, Jun Yang, Yang-yang Huang","doi":"10.3760/CMA.J.CN113030-20190618-00008","DOIUrl":"https://doi.org/10.3760/CMA.J.CN113030-20190618-00008","url":null,"abstract":"Objective \u0000To evaluate the effect of long-chain non-coding RNA (LncRNA) UCA1 on the proliferation, apoptosis and radiosensitivity of lung cancer cell and to explore the underlying mechanism. \u0000 \u0000 \u0000Methods \u0000qRT-PCR was used to detect the expression of UCA1 and miR-513a-5p in lung cancer cell A549, H1299 and normal human lung cell HBE. The si-con group (transfected si-con), si-UCA1 group (transfected si-UCA1), miR-513a-5p group (transfected miR-513a-5p mimics), miR-NC group (transfected miR-NC), IR+ si-con group (transfected si-con, and irradiated), IR+ si-UCA1 group (transfected miR-NC and irradiated), IR+ miR-513a-5p group (transfected miR-513a-5p mimics and irradiated), IR+ miR-NC group (transfected miR-NC and irradiated), IR+ si-UCA1+ anti-miR-513a-5p group (co-transfected si-UCA1, anti-miR-513a-5p and irradiated) were transfected into the A549 and H1299 cells by liposome method, and then the cells in certain groups were subject to 4Gy irradiation. The cell proliferation of each group was detected by MTT assay. The sensitivity enhancement ratio was assessed by clone formation assay. The cell apoptosis of each group was detected by flow cytometry. The fluorescence activity of each group was detected by dual-fluorescein gene detection assay. \u0000 \u0000 \u0000Results \u0000Compared with human normal lung cell HBE, the expression levels of UCA1 were significantly up-regulated in the lung cancer cell A549 and H1299(both P<0.05), whereas those of miR-513a-5p were significantly down-regulated (both P<0.05). Inhibition of UCA1 and overexpression of miR-513a-5p significantly inhibited cell proliferation, promoted cell apoptosis and increased the sensitivity of radiation exposure of A549 and H1299(sensitivity enhancement ratio=1.897, 2.146 and 1.615, 1.872). miR-513a-5p could suppress the fluorescence activity of wild-type UCA1 cells, and UCA1 could negatively regulate the expression of miR-513a-5p. Inhibition of miR-513a-5p could reverse the enhancement effect of inhibiting UCA1 upon the radiosensitivity of lung cancer cells. \u0000 \u0000 \u0000Conclusions \u0000Inhibition of LncRNA UCA1 can enhance the sensitivity of radiation exposure to lung cancer cells. The mechanism may be related to the targeted inhibition of miR-513a-5p. \u0000 \u0000 \u0000Key words: \u0000UCA1 gene; miR-513a-5p gene; Radiosensitivity; Lung cancer cell line","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"289-293"},"PeriodicalIF":0.0,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48638155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Research status of ultrasound-guided radiotherapy for tumors 超声引导肿瘤放射治疗的研究现状
Chinese Journal of Radiation Oncology Pub Date : 2020-04-15 DOI: 10.3760/CMA.J.CN113030-20181125-00014
Hongfei Sun, Xinye Ni, Jianhua Yang
{"title":"Research status of ultrasound-guided radiotherapy for tumors","authors":"Hongfei Sun, Xinye Ni, Jianhua Yang","doi":"10.3760/CMA.J.CN113030-20181125-00014","DOIUrl":"https://doi.org/10.3760/CMA.J.CN113030-20181125-00014","url":null,"abstract":"Image-guided techniques are critical to improving the accuracy of radiotherapy for tumors. Ultrasound images have been gradually applied in the set-up verification of clinical radiotherapy and adaptive radiotherapy because of the real-time, reproducible and non-radiative characteristics. In this paper, the application of ultrasound image-guided technology in radiotherapy was classified and analyzed, and the latest research progress was introduced. \u0000 \u0000Key words: \u0000Neoplasm/ultrasound-guided radiotherapy; Research status","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"317-320"},"PeriodicalIF":0.0,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44616725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Current situation and research progress on postoperative adjuvant radiotherapy for thymoma 胸腺瘤术后辅助放疗的现状及研究进展
Chinese Journal of Radiation Oncology Pub Date : 2020-04-15 DOI: 10.3760/CMA.J.CN113030-20190614-00012
Q. Zeng, Y. Zhai, Xiao-dan Wang, Q. Feng
{"title":"Current situation and research progress on postoperative adjuvant radiotherapy for thymoma","authors":"Q. Zeng, Y. Zhai, Xiao-dan Wang, Q. Feng","doi":"10.3760/CMA.J.CN113030-20190614-00012","DOIUrl":"https://doi.org/10.3760/CMA.J.CN113030-20190614-00012","url":null,"abstract":"Surgical resection is the most important treatment of thymoma. However, the role of postoperative adjuvant radiotherapy (PORT) has been controversial. The survival benefits of two-dimensional radiotherapy are not significant. However, precision radiotherapy has significantly changed tumor radiotherapy. The value of PORT for thymoma may also be altered. At present, the effect of radiotherapy in patients with positive surgical margins or inoperable resection is confirmed. For patients with complete surgical resection, Masaoka-Koga stage Ⅰ patients do not require PORT. Whether PORT should be given for stage Ⅱ patients remains debated if stage Ⅱb, large volume and B2/B3 type were considered during radiotherapy. The role of PORT for stage Ⅲ patients is also in disputed, whereas a majority of findings support the application of PORT. Precision technology is recommended during PORT. The clinical target volume suggests that the three-dimensional expansion of the tumor bed is 0.5 cm, including the mediastinal pleura involved by the tumor and 0.5-1.0 cm along the anterior and posterior direction of the mediastinal pleura, the cranial and caudal direction, the lung side is expanded within the 0.5 cm, and the vascular wall around the tumor and part of the vascular space, so as to avoid including too much normal tissue. The dose for complete resection is 45-50 Gy and 54-60 Gy or slightly higher for incomplete resection, which may increase the benefits and reduce the risk of PORT.The application of new radiotherapy techniques such as particle therapy can gain the advantage of dosimetric distribution, and whether it can be transformed into clinical benefits needs to be further explored. \u0000 \u0000Key words: \u0000Thymoma/radiotherapy; Radiotherapy, postoperative; Progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"308-312"},"PeriodicalIF":0.0,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41522835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical application and evaluation of automatic segmentation model based on deep learning for breast cancer radiotherapy 基于深度学习的自动分割模型在乳腺癌放疗中的临床应用及评价
Chinese Journal of Radiation Oncology Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.009
Xinyuan Chen, K. Men, Yu Tang, Shulian Wang, J. Dai
{"title":"Clinical application and evaluation of automatic segmentation model based on deep learning for breast cancer radiotherapy","authors":"Xinyuan Chen, K. Men, Yu Tang, Shulian Wang, J. Dai","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.009","url":null,"abstract":"Objective \u0000In this study, the deep learning algorithm and the commercial planning system were integrated to establish and validate an automatic segmentation platform for clinical target volume (CTV) and organs at risk (OARs) in breast cancer patients. \u0000 \u0000 \u0000Methods \u0000A total of 400 patients with left and right breast cancer receiving radiotherapy after breast-conserving surgery in Cancer Hospital CAMS were enrolled in this study. A deep residual convolutional neural network was used to train CTV and OARs segmentation models. An end-to-end deep learning-based automatic segmentation platform (DLAS) was established. The accuracy of the DLAS platform delineation was verified using 42 left breast cancer and 40 right breast cancer patients. The overall Dice Similarity Coefficient (DSC) and the average Hausdorff Distance (AHD) were calculated. The relationship between the relative layer position and the DSC value of each layer (DSC_s) was calculated and analyzed layer-by-layer. \u0000 \u0000 \u0000Results \u0000The mean overall DSC and AHD of global CTV in left/right breast cancer patients were 0.87/0.88 and 9.38/8.71 mm. The average overall DSC and AHD range for all OARs in left/right breast cancer patients were ranged from 0.86 to 0.97 and 0.89 to 9.38 mm. The layer-by-layer analysis of CTV and OARs reached 0.90 or above, indicating that the doctors were only required to make slight or no modification, and the DSC_s ≥ 0.9 of CTV automatic delineation accounted for approximately 44.7% of the layers. The automatic delineation range for OARs was 50.9%-89.6%. For DSC_s< 0.7, the DSC_s values of CTV and the regions of interest other than the spinal cord were significantly decreased in the boundary regions on both sides (layer positions 0-0.2, and 0.8-1.0), and the level of decrease toward the edge was more pronounced. The spinal cord was delineated in a full-scale manner, and no significant decrease in DSC_s was observed in a particular area. \u0000 \u0000 \u0000Conclusions \u0000The end-to-end automatic segmentation platform based on deep learning can integrate the breast cancer segmentation model and achieve excellent automatic segmentation effect. In the boundary areas on both sides of the superior and inferior directions, the consistency of the delineation decreases more obviously, which needs to be further improved. \u0000 \u0000 \u0000Key words: \u0000Automatic segmentation; Deep learning; Breast neoplasm/radiotherapy","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"197-202"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42848054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary study of intensity-modulated carbon ion reirradiation for locoregionally recurrent nasopharyngeal carcinoma after definitive IMRT——Clinical experience from Shanghai Proton Heavy Ion Hospital 调强碳离子再照射治疗鼻咽癌局部复发的初步研究——上海质子重离子医院的临床经验
Chinese Journal of Radiation Oncology Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.001
Jiyi Hu, Jing Gao, Weixu Hu, Jing Yang, X. Guan, Xianxin Qiu, L. Kong, J. Lu
{"title":"Preliminary study of intensity-modulated carbon ion reirradiation for locoregionally recurrent nasopharyngeal carcinoma after definitive IMRT——Clinical experience from Shanghai Proton Heavy Ion Hospital","authors":"Jiyi Hu, Jing Gao, Weixu Hu, Jing Yang, X. Guan, Xianxin Qiu, L. Kong, J. Lu","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.001","url":null,"abstract":"Objective \u0000To evaluate the short-term efficacy and toxicities of intensity-modulated carbon ion radiotherapy (IMCT) for patients with locoregionally recurrent nasopharyngeal carcinoma after intensity-modulated radiotherapy (IMRT). \u0000 \u0000 \u0000Methods \u0000A total of 112 patients with locoregionally recurrent nasopharyngeal carcinoma undergoing salvaging IMCT between May 2015 and February 2018were enrolled in the study. All patients previously received one course of definitive X-ray IMRT. Among them, 10 patients (9%) were diagnosed with stage Ⅰ, 26 patients (23%) with stage Ⅱ, 41 patients (37%) with stage Ⅲ and 35 patients (31%) with stage Ⅳnasopharyngeal carcinoma, respectively. The median age of the cohort was 48 years (range, 17-70 years) old. The median dose to the gross tumor volume (GTV) was 60 GyE (range, 50-69 GyE). \u0000 \u0000 \u0000Results \u0000With a median follow-up time of 20 months (range, 5-45 months), 20 patients died and 42 patients developed local recurrence. The 2-year overall survival (OS) and local progression-free survival (LPFS) rates were 85% and 52%. Both univariate and multivariate analyses demonstrated that stage Ⅳ disease was associated with significantly worse OS. No predictors were found for LPFS. No acute toxicity of grade 3 or higher was observed during reirradiation. Severe (grade 3 or above) late toxicities included xerostomia (n=1), hearing impairment (n=2), temporal lobe injury (n=1) and mucosal necrosis (n=19). \u0000 \u0000 \u0000Conclusions \u0000IMCT is an efficacious and safe treatment for patients with locoregionally recurrent nasopharyngeal carcinoma with acceptable toxicity profile. Long-term follow-up is necessary to further evaluate the long-term efficacy and late toxicities. \u0000 \u0000 \u0000Key words: \u0000Nasopharyngeal neoplasm/intensity-modulated carbon ion radiotherapy; Second-course radiotherapy; Treatment outcome","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"161-165"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44573858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of local recurrence pattern for limited stage small cell lung cancer after IMRT plus chemotherapy 有限期小细胞肺癌放疗加化疗后局部复发模式分析
Chinese Journal of Radiation Oncology Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.004
W. Yan, Xuan Liu, Zongmei Zhou, Yuxia Wang, Z. Xiao, Q. Feng, Dong-fu Chen, L. Ji-ma, Jun Liang, L. Deng, Tao Zhang, Wenqing Wang, N. Bi, Xin Wang, Xiaozhen Wang, Z. Hui, Luhua Wang
{"title":"Analysis of local recurrence pattern for limited stage small cell lung cancer after IMRT plus chemotherapy","authors":"W. Yan, Xuan Liu, Zongmei Zhou, Yuxia Wang, Z. Xiao, Q. Feng, Dong-fu Chen, L. Ji-ma, Jun Liang, L. Deng, Tao Zhang, Wenqing Wang, N. Bi, Xin Wang, Xiaozhen Wang, Z. Hui, Luhua Wang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.004","url":null,"abstract":"Objective \u0000To investigate localized regional recurrence after chemotherapy and chest radiotherapy in limited stage small cell lung cancer (LS-SCLC), and explore the relationship between recurrence location and radiotherapy and chemotherapy and its influencing factors. \u0000 \u0000 \u0000Methods \u0000From 2006 to 2014, pathological LS-SCLC treated in CAMS, 125 patients had local recurrence, Kaplan-Meier statistical method was used to analyze the survival rate and PFS of each recurrence site. Log-rank was used to compare the survival rate of each group. Univariate analysis includes Chi-squareand t-test for the factors for the recurrence site. Multivariate analysis using Logistic regression. \u0000 \u0000 \u0000Results \u0000The 1-, 2-and 5-year overall survival rates were 92.0%, 46.4% and 14.7%, respectively. The median progression time was 12.96 months, The median survival time after progression was 11.5 months, and the 1-, 2-, and 5-year overall survival rates were 45.0%, 23.0%, and 10.0%, respectively. The recurrence sites include intrapulmonary recurrence (67 patients), regional lymph nodes (21 patients), simultaneous intrapulmonary and regional lymph nodes (28 patients), and contralateral or supraclavicular lymph nodes (9 patients). The median survival time were 23.96 months, 24.76 months, 23.23 months, and 18.66 months, and the 2-year survival rates were 49%, 52%, 46%, and11%, respectively (P=0.000, 0.004, 0.008). In 6 patients (4.0%), 5 patients were located in the supraclavicular region, and 1 patient (0.8%) in the field. \u0000 \u0000 \u0000Conclusions \u0000For LS-SCLC undergoing IMRT and chemotherapy, the local failure location is mainly located in the pulmonary, and further treatment of the split dose and targets requires further clinical exploration. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms/radiochemoradiation; Radiotherapy, intensity-modulated; Patterns of failure","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"175-178"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46687746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of a magnetic field on the dose distribution using the Bebig60Co HDR sources 磁场对Bebig60Co HDR源剂量分布的影响
Chinese Journal of Radiation Oncology Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.008
Zhenguo Cui, Jiayi Chen, W. Yun, Qi Liu, Yanling Bai
{"title":"The impact of a magnetic field on the dose distribution using the Bebig60Co HDR sources","authors":"Zhenguo Cui, Jiayi Chen, W. Yun, Qi Liu, Yanling Bai","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.008","url":null,"abstract":"ObjectiveTo evaluate the impact of an external magnetic field on the dose distribution and electronic disequilibrium region around a Bebig type 60Co HDR brachytherapy source and to judge the feasibility of applying MRI scanner during brachytherapy.MethodsThe source model was established based on the Monte Carlo package Geant4 software. The simulated geometries consisted of the 60Co source inside a water phantom of 10.0cm×10.0cm×10.0cm in size. The magnetic field strength of the 0T, 1.5T and 3.0T was considered, respectively. The voxels with a size of 0.2 mm, 0.5 mm and 0.5 mm were established along the x-, y-and z-axis. The influence of the magnetic field on the Kerma (kinetic energy released to matter) distribution and dose distribution within the 10.0mm region from the source center was evaluated. Furthermore, the ratio of the Kerma to dose as a function of the distance to the center source was acquired.ResultsThe 1.5T magnetic field exerted no effect on the dose distribution adjacent to 60Co HDR brachytherapy source, whereas3.0T magnetic field caused significant increase in the dose distribution within r<6 mm from the source center. The dose distribution was increased by 40% at r=5.4 mm from the source center. The ratio of Kerma to dose was less than 1 within the region of 1.2 mm<r<6.0 mm, suggesting that 3.0T magnetic field can lead to electronic disequilibrium within a larger region from the source center.ConclusionsFor Bebig 60Co HDR brachytherapy source, it is safe and reliable to apply1.5T external magnetic field. Nevertheless, 3.0T magnetic field can cause high dose risk. Consequently, safety assessment and verification should be delivered prior to clinical application.Key words: Magnetic field; Brachytherapy; Dose; Kerma","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"193-196"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43264875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage IVA thymoma 调强放疗治疗IVA期胸腺瘤的疗效和安全性初步分析
Chinese Journal of Radiation Oncology Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.006
D. Chang, Ping Li, Jing Li, Yong Wang, J. Cui, Yingjie Wang, T. Xia
{"title":"Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage IVA thymoma","authors":"D. Chang, Ping Li, Jing Li, Yong Wang, J. Cui, Yingjie Wang, T. Xia","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.006","url":null,"abstract":"Objective \u0000To preliminarily evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) in the treatment of inoperable stage ⅣA thymoma. \u0000 \u0000 \u0000Methods \u0000A retrospective analysis of 15 patients with inoperable stage ⅣA thymoma receiving IMRT from January 2010 to December 2017 was performed. Among them, 9 patients were male and 6 female, aged 31-83 years with a medianof 59 years. The dose of radiotherapy was 50Gy/60Gy/70Gy/15-20 fractions for PTV/CTV/GTV. The short-term efficacy, overall survival rate and adverse reactions were analyzed. \u0000 \u0000 \u0000Results \u0000The follow-up rate was 100%. The median follow-up time was 48 months. The short-term partial remission rate was 93%(14/15). The 1-, 3-and 5-year overall survival rates were 100%, 75% and 75%, respectively. One patient presented with grade 3 hematological reaction. Four patients died of tumors. \u0000 \u0000 \u0000Conclusion \u0000Preliminary findings demonstrate that IMRT is an efficacious and safe treatment of stageⅣA thymoma, which can be applied for patients with unresectable thymoma. \u0000 \u0000 \u0000Key words: \u0000Thymoma/intensity-modulated radiotherapy; Treatment outcome; Safety","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"184-186"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48420988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信